论文部分内容阅读
30只大鼠分成5组,分别用铂牛血清白蛋白结合物(Pt-BSA)及甲苯二异氰酸酯牛血清白蛋白结合物(TDI-BSA)加弗氏完全佐剂(CFA),以及单用BSA-CFA,NS,CFA作为对照给大鼠腹腔内注射进行免疫。分别于免疫前、免疫后2周、4周采血。用酶联免疫吸附实验(ELISA)以铂人血清白蛋白结合物(Pt-HSA)、甲苯二异氰酸酯人血清白蛋白结合物(TDI-HSA)为抗原,单克隆鼠抗大鼠IgG-HRPO抗体进行抗原特异性IgG(S-IgG)测定。结果发现用Pt-BSA、TDI-BSA致敏动物后,体内存在S-IgG,其水平随免疫时间的延长或加强免疫而递增。对照组不存在这种S-IgG的增加。用S-IgG抑制试验证明这种抗体具有明显的半抗原特异性。
Thirty rats were divided into five groups and treated with platinum-BSA and TDI-BSA plus Freund’s complete adjuvant (CFA) BSA-CFA, NS, CFA as a control to rats for intraperitoneal injection for immunization. Before immunization, 2 weeks after immunization, 4 weeks blood sampling. The mouse anti-rat IgG-HRPO antibody was detected by enzyme-linked immunosorbent assay (ELISA) using platinum human serum albumin conjugate (Pt-HSA) and toluene diisocyanate human serum albumin conjugate (TDI- Antigen-specific IgG (S-IgG) assays were performed. As a result, it was found that S-IgG was present in vivo after sensitizing animals with Pt-BSA and TDI-BSA, and the level of S-IgG increased as the immunization time or booster immunization progressed. There was no such increase in S-IgG in the control group. S-IgG inhibition test proved that this antibody has obvious hapten specificity.